



**Supplementary Figure S1** BDG = 1,3-Beta-D-glucan; BSW = biomedical support worker; BMS = biomedical scientist; MRL = United Kingdom Health Security Agency (UKHSA) Mycology Reference Laboratory; OM = outcome metric; PM = process metric; IM = input metric (potential confound shown with dotted line)



It is clear that **Stage 1** (sending samples to the MRL by road) and **Stage 3** (receiving hardcopy reports back by post) are the greatest barriers to achieving the target aggregate TAT of 5 days.

**Supplementary Figure S2** Durations of stages of the BDG testing pathway showing mean for each stage and aggregate TAT target for comparison. The sample is April 2021 (n=70 test requests after 1 extreme outlier removed), when the mean aggregate TAT was 10.1 days.



**Stage 3 Stage 1** Stage 2 Stage 4 Stage 5

**Supplementary Figure S3** Pareto chart of the median duration in days for the stages of the pathway.

The sample is April 2021 (n=70 test requests after 1 extreme outlier removed), when the mean aggregate TAT was 10.1 days (median 9.5 days).